QRFT1.350%
as of Jul 8
JNJ
GrowthJOHNSON & JOHNSON
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Close · 3M
+2.57%
Held by 3 AI ETFs
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals27
Win rate41% (11/27)
Avg buy return+0.17%
QRFT · Accumulation · 5d
JOHNSON & JOHNSON, presently trading at its 52-week high of $263.04 after a 75.6% one-year surge and a 14.7% gain in the last 30 days, shows significant upward momentum. This sustained price trajectory, combined with JNJ’s 26.26% return on equity and 7.87% revenue growth, likely signals strong momentum and quality factors to Qraft AI's methodology. Despite a price-to-earnings ratio of 29.79, QRFT's AI, which integrates traditional factors with proprietary alternative-data overlays, has been gradually accumulating the stock. The consistent increase in weight from 1.2400% to 1.3600% between June 23 and July 2, with minor adjustments, reflects the AI's continuous positive assessment of JNJ within its diversified large-cap core portfolio.
weight 1.240% → 1.360% (+0.120 pp)·stock up 18.0% in the 30 days before
Jul 2·entry $263.04·now $248.82Fresh
-5.41%
since Jul 2
QRFT · Accumulation · 5d
The observed gradual accumulation in Johnson & Johnson's weight within QRFT, steadily increasing from 1.17% to 1.33% over eight trading days, signals a measured approach by Qraft's AI. This incremental buying occurs as JNJ trades at the very top of its 52-week range and after a 75.6% one-year return, suggesting the AI's momentum and quality overlays are identifying continued positive drivers. Qraft's AI, blending traditional factors with proprietary alternative data, likely acknowledges JNJ's 26.26% ROE and 7.87% revenue growth as compelling indicators, warranting increased allocation despite a PER of 29.79. The fund's weekly rebalancing cycle and broad large-cap core style enable these calibrated adjustments, allowing the AI to increase exposure to this health care company without abrupt shifts.
weight 1.170% → 1.300% (+0.130 pp)·stock up 13.6% in the 30 days before
Jul 1·entry $253.98·now $248.82Fresh
-2.03%
since Jul 1
QRFT · Accumulation · 5d
The weight of Johnson & Johnson in QRFT reflects a measured, week-long accumulation from 1.16% to 1.33% through late June, followed by a slight recalibration to 1.29%. This incremental increase aligns with Qraft AI's blend of traditional factors and proprietary alternative data, which likely identified persistent quality and momentum signals in JNJ, evidenced by its 26.26% ROE and 7.87% revenue growth. Despite the stock trading at $253.97, near 98% of its 52-week high of $258.51, QRFT's weekly rebalancing mechanism allowed for a gradual build-up within its diversified, large-cap core mandate. The minor reduction toward month-end potentially indicates the AI adjusting for the stock's relatively high 27.53 PER, balancing exposure as it approaches its valuation limits.
weight 1.160% → 1.290% (+0.130 pp)·stock up 12.7% in the 30 days before
Jun 30·entry $253.97·now $248.82Fresh
-2.03%
since Jun 30
QRFT · Accumulation · 5d
Qraft Technologies’ AI-driven QRFT, which incorporates traditional factors like momentum and quality with proprietary alternative data overlays, progressively increased its exposure to Johnson & Johnson. The fund's weekly rebalancing framework allowed its algorithm to gradually build its position in JNJ, likely reacting to sustained positive signals from the company's strong price performance and underlying financial health. JNJ's 1-year return of +66.5% would heavily register with the momentum factor embedded in QRFT’s methodology, while its 26.26% Return on Equity supports a quality assessment, even as the stock reaches its 52-week high. The consistent, incremental weight adjustments from 1.16% to 1.33% within QRFT’s ~300 US large-cap portfolio indicate the AI’s continuous validation of JNJ’s suitability based on these combined signals.
weight 1.210% → 1.330% (+0.120 pp)·stock up 12.0% in the 30 days before
Jun 29·entry $258.51·now $248.82Fresh
-3.75%
since Jun 29
QRFT · Accumulation · 6d
JNJ's financial profile, featuring a PER of 27.53, PBR of 6.13, and Revenue Growth of 7.87% with a ROE of 26.26%, aligns with the quality and growth factors central to QRFT's AI-driven strategy, which combines traditional metrics with proprietary alternative-data overlays. This accumulation occurred even as JNJ reached its 52-week high of $254.66, reflecting a 10.3% return over 30 days, suggesting QRFT's AI may have identified continued positive signals beyond conventional valuation metrics. Despite the stock trading at the top of its 52-week range, the AI-managed QRFT gradually increased its JNJ weight from 1.2000% to 1.3300% between June 16 and June 26, indicating a measured confidence in the stock's continued performance within its diversified large-cap core portfolio.
weight 1.200% → 1.330% (+0.130 pp)·stock up 10.1% in the 30 days before
Jun 26·entry $254.66·now $248.82Fresh
-2.29%
since Jun 26
+1.61%
since Jun 25
+3.24%
since Jun 24
QRFT · Weight increase · 2d
stock up 3.2% in the 30 days before
Jun 23·entry $239.08·now $248.82Drifting
+4.07%
since Jun 23
QRFT · Weight increase · 2d
stock up 2.3% in the 30 days before
Jun 17·entry $234.20·now $248.82Drifting
+6.24%
since Jun 17
+4.40%
since Jun 11
+4.33%
since Jun 10
+4.99%
since Jun 9
PQUS · Weight increase · 3d
Pictet Asset Management's AI ranking system for PQUS has driven a consecutive increase in Johnson & Johnson's weight, reflecting a systematic re-evaluation within its periodic rebalancing cycle for its portfolio of around 165 US large caps. This deliberate shift, observed in the move from 0.83% to 0.86% over recent days, suggests the AI identifies sustained positive signals, potentially valuing the company's 26.26% Return on Equity as a key factor in its increased ranking. Even with Johnson & Johnson's stock currently trading at 95% of its 52-week high, the AI's logic, layered with sector-balance and concentration rules, prioritizes fundamental strength perceived in the Health Care sector leader.
weight 0.820% → 0.860% (+0.040 pp)·stock up 7.6% in the 30 days before
Jul 19·entry $248.82·now $248.82Fresh
0.00%
since Jul 19
PQUS · Weight increase · 2d
The specific pattern for Johnson & Johnson in PQUS shows a subtle, two-day weight increase from 0.82% to 0.84% between July 16th and 18th. This measured upward adjustment aligns with Pictet Asset Management's stated approach for PQUS, which emphasizes measured turnover and periodic rebalancing rather than daily, volatile shifts. Despite the stock trading at 95% of its 52-week high after a 63.0% annual return, Johnson & Johnson's 26.26% ROE and 8.06% revenue growth likely maintained its favorable ranking within the AI system. Such a gradual increase suggests the AI system, guided by its sector-balance and concentration rules for its large-cap universe, carefully adjusted exposure as new data was processed, avoiding aggressive moves into a stock with a 28.95 PER.
weight 0.820% → 0.840% (+0.020 pp)·stock up 7.6% in the 30 days before
Jul 18·entry $248.82·now $248.82Fresh
0.00%
since Jul 18
PQUS · Weight decrease · 3d
JNJ's weight in PQUS demonstrates a gradual decrease from 0.86% on July 10th to 0.83% by July 12th, after an earlier temporary increase. This measured adjustment by Pictet's AI ranking system reflects a strategic re-evaluation of JNJ's position, as the stock now trades at 96% of its 52-week high following a 68.6% return over the last year. While JNJ maintains a 7.87% revenue growth and 26.26% ROE, the fund's sector-balance and concentration rules likely prompted the subtle reduction in response to the stock's current valuation metrics, including a PER of 29.45 and PBR of 6.13. This measured turnover approach ensures the ETF manages exposure to a stock that has seen considerable price appreciation, aligning with its periodic rebalancing methodology for US large-cap equities.
weight 0.880% → 0.830% (-0.050 pp)·stock up 8.4% in the 30 days before
Jul 12·entry $257.77·now $248.82
-3.47%
since Jul 12
PQUS · Weight decrease · 2d
The observed pattern in PQUS for JNJ shows a gradual, two-day decrease in weight from 0.86% to 0.84% following earlier slight fluctuations in July. This measured reduction likely stems from Pictet Asset Management's AI ranking system recalibrating holdings as JNJ trades at 96% of its 52-week high, following a +11.3% return over the past 30 days. With JNJ's PER at 29.45 and PBR at 6.13, the AI system may be moderating its exposure to a stock with an elevated valuation within the Health Care sector, adhering to its sector-balance and concentration rules. The fund’s design for measured turnover and periodic, rather than daily, rebalances is consistent with this type of incremental adjustment to a position that has experienced substantial price appreciation.
weight 0.880% → 0.840% (-0.040 pp)·stock up 8.4% in the 30 days before
Jul 11·entry $257.77·now $248.82
-3.47%
since Jul 11
PQUS · Accumulation · 5d
Trading at $253.97, JNJ is currently at 98% of its 52-week high of $258.51, having delivered a 66.7% return over the past year, alongside a recent 10.9% gain in 30 days. Despite this significant appreciation, the AI ranking system employed by PQUS has initiated a gradual accumulation of JNJ, incrementally raising its weighting from 0.77% to 0.88% over eight days. This measured increase suggests the AI algorithm, which incorporates sector-balance and concentration rules for its 165 US large-cap holdings, identifies continued appeal in JNJ's underlying fundamentals, such as its 7.87% revenue growth and 26.26% return on equity, even with a price-to-earnings ratio of 27.53. The newer fund's strategy, emphasizing periodic rebalancing and measured turnover within the US large-cap universe, aligns with this slow, consistent build-up in the Health Care sector, indicating a deliberate, rule-based decision rather than a rapid response to recent price movements.
weight 0.770% → 0.880% (+0.110 pp)·stock up 13.6% in the 30 days before
Jul 1·entry $253.98·now $248.82Fresh
-2.03%
since Jul 1
PQUS · Accumulation · 5d
The detected weight change in JNJ shows a consistent, incremental accumulation by PQUS, rising from 0.76% to 0.87% over an eight-day period before stabilizing. This measured increase aligns with PQUS's investment strategy, which utilizes an AI ranking system for US large-cap stocks with a focus on measured turnover and periodic rebalances, rather than daily adjustments. Even as JNJ reached its 52-week high of $258.51 after a 66.5% one-year return, the AI likely continued to identify it as a valuable holding due to underlying financial strength, including 7.87% revenue growth and 26.26% ROE. The AI's sector-balance and concentration rules, coupled with a preference for deliberate portfolio adjustments, influenced the gradual additions instead of a singular, large purchase. Consequently, the fund carefully built its position in this specific Health Care stock, reflecting a cautious yet persistent confidence from its AI-driven methodology in JNJ's sustained performance at its current price level.
weight 0.760% → 0.870% (+0.110 pp)·stock up 12.7% in the 30 days before
Jun 30·entry $253.97·now $248.82Fresh
-2.03%
since Jun 30
PQUS · Accumulation · 5d
Johnson & Johnson’s PER of 27.53, PBR of 6.13, Revenue Growth of 7.87%, and ROE of 26.26% suggest a financially sound US large-cap entity. These specific fundamental metrics likely factor positively into Pictet Asset Management’s AI ranking system, which targets US large-cap companies for PQUS while adhering to sector-balance and concentration rules. The gradual accumulation of JNJ within PQUS, with its weighting increasing from 0.76% to 0.87% over seven days, aligns with the fund’s stated style of measured turnover rather than swift changes, even as JNJ reached $254.66, precisely 100% of its 52-week high, following a 30-day return of +10.3%. This systematic increase indicates PQUS's AI system identified JNJ's sustained financial health and growth momentum as justifying a higher allocation within the portfolio, despite its current valuation and recent price appreciation.
weight 0.760% → 0.870% (+0.110 pp)·stock up 12.0% in the 30 days before
Jun 29·entry $258.51·now $248.82Fresh
-3.75%
since Jun 29
PQUS · Accumulation · 5d
The observed gradual accumulation of JNJ in PQUS, with its weight increasing from 0.76% to 0.87% over eight consecutive trading days, indicates a considered adjustment rather than an abrupt shift. At its current price of $254.66, marking 100% of its 52-week range after a 62.1% one-year return, JNJ's valuation metrics, including a PER of 27.53 and PBR of 6.13, suggest a mature yet growing company. This measured increase aligns with Pictet Asset Management's AI ranking system, which, operating with periodic rebalances and measured turnover for its ~165 US large caps, would incrementally integrate JNJ's 26.26% ROE and 7.87% revenue growth without a sudden, large allocation, respecting its sector-balance and concentration rules. The pattern suggests the AI is patiently building exposure, acknowledging both JNJ's market performance and fundamental figures within the fund's specific operational constraints.
weight 0.760% → 0.870% (+0.110 pp)·stock up 10.1% in the 30 days before
Jun 28·entry $258.51·now $248.82Fresh
-3.75%
since Jun 28
PQUS · Weight increase · 4d
The weight increase for JNJ in PQUS exhibited a gradual, stepped ascent from 0.76% to 0.83% over four consecutive days, following a period of stable weighting. This measured accumulation, rather than an abrupt shift, aligns directly with Pictet Asset Management's strategy for PQUS, which emphasizes measured turnover within its US large-cap universe. Even with JNJ trading at its 52-week high of $254.66 and a 1-year return of 62.1%, the AI ranking system likely identified sustained fundamental drivers, such as a 26.26% ROE and 7.87% revenue growth, indicating underlying value. The incremental nature of these adjustments is consistent with the fund's periodic rebalancing and its layered sector-balance and concentration rules, suggesting a deliberate re-calibration based on sustained positive signals from the AI system.
weight 0.760% → 0.830% (+0.070 pp)·stock up 10.1% in the 30 days before
Jun 27·entry $258.51·now $248.82Fresh
-3.75%
since Jun 27
PQUS · Weight increase · 3d
Johnson & Johnson's stock is currently trading at $244.88, positioned at 99% of its 52-week high, following a 30-day return of +6.3% and a 1-year return of +56.3%. This upward price trajectory and proximity to its yearly peak coincided with PQUS, managed by Pictet Asset Management, sequentially increasing JNJ's weight from 0.76% to 0.82% over June 24th to June 26th, 2026, after several days at a static level. The fund's AI ranking system, designed for US large-cap selection within its sector-balanced and concentration-rule framework, likely identified JNJ as increasingly attractive based on its 7.87% revenue growth and 26.26% ROE, even with a PER of 27.53. This sustained upward signal from JNJ's underlying metrics, coupled with its recent market performance, evidently led the AI to progressively allocate more capital during its periodic rebalances, pushing the company's weighting higher within the ~165 US large-cap portfolio.
weight 0.760% → 0.820% (+0.060 pp)·stock up 10.1% in the 30 days before
Jun 26·entry $254.66·now $248.82Fresh
-2.29%
since Jun 26
+1.61%
since Jun 25
PQUS · Weight increase · 2d
stock up 3.6% in the 30 days before
Jun 7·entry $232.16·now $248.82Drifting
+7.18%
since Jun 7
AIEQ · Weight increase · 2d
JNJ currently trades at $253.04, sitting at 95% of its 52-week high after a substantial 10.9% gain over 30 days and a 63.0% increase over the past year. This upward price trajectory, paired with JNJ's 8.06% revenue growth and high 26.26% return on equity, likely generated a flow of positive textual data—news, analyst commentary, and social posts—for AIEQ's IBM Watson NLP engine. This sustained positive signal, translated through the daily ranking system, prompted AIEQ's risk overlay to incrementally increase JNJ's weight, briefly reaching 0.49% as conviction built despite the stock's valuation at a PER of 28.95 and PBR of 6.13. Given AIEQ's broad market, fundamentals and sentiment hybrid style with daily rebalancing and high turnover, this swift adjustment reflects the fund's strategy of dynamically allocating capital based on real-time, AI-driven insights.
weight 0.460% → 0.480% (+0.020 pp)·stock up 7.6% in the 30 days before
Jul 19·entry $248.82·now $248.82Fresh
0.00%
since Jul 19
AIEQ · Weight decrease · 2d
AIEQ exhibits a pattern of consecutive weight decreases in Johnson & Johnson, specifically from 0.49% to 0.46% over the last few days, following an earlier reduction from 0.50% to 0.48%. This series of calibrated adjustments aligns with AIEQ's high-turnover portfolio, which performs daily rebalancing based on its IBM Watson NLP ranking. The fund's system likely re-evaluated JNJ's standing given its current price of $249.97, nearing 94% of its 52-week high after a 12.0% 30-day return. While JNJ maintains a 26.26% ROE, its PER of 29.45 and PBR of 6.13 might indicate that the AI’s sentiment analysis or risk overlay detected diminishing relative value or growing caution in news and social posts. This incremental reduction reflects the ETF's hybrid fundamentals and sentiment approach in managing exposure to individual US equities.
weight 0.490% → 0.460% (-0.030 pp)·stock up 6.1% in the 30 days before
Jul 16·entry $249.97·now $248.82
-0.46%
since Jul 16
AIEQ · Accumulation · 5d
JNJ's financial indicators, including its 27.53 PER, 6.13 PBR, 7.87% revenue growth, and 26.26% ROE, align with AIEQ's broad market, fundamentals + sentiment hybrid style. IBM Watson NLP, which drives AIEQ's daily rebalancing, likely detected escalating positive sentiment or favorable fundamental developments across its diverse data sources for Johnson & Johnson. This continuous analysis prompted AIEQ to gradually accumulate JNJ, increasing its allocation from 0.5600% to 0.6200% between June 17 and June 28. The fund's heightened exposure materialized even as JNJ's current price of $254.66 placed it at 100% of its 52-week high, following a +10.3% 30-day return. This indicates the AI's sustained conviction, driven by its underlying assessment, regardless of the stock trading at peak levels.
weight 0.560% → 0.620% (+0.060 pp)·stock up 10.1% in the 30 days before
Jun 28·entry $258.51·now $248.82Fresh
-3.75%
since Jun 28
AIEQ · Weight increase · 3d
JNJ's ROE of 26.26% and 7.87% revenue growth present a picture of strong underlying fundamentals, aligning with AIEQ's hybrid style that considers both fundamental metrics and market sentiment. IBM Watson NLP, ingesting vast amounts of data including news and social posts, likely detected a sustained positive shift in sentiment surrounding JNJ, driving its daily ranking. This sentiment likely reinforced JNJ's position even as its price ascended, reaching a 52-week high of $254.66 after a 30-day return of +10.3%. Consequently, EquBot's risk overlay permitted a consecutive weight increase in JNJ from 0.58% to 0.60% between June 24 and June 26, reflecting conviction in its continued upward trajectory despite the elevated PER of 27.53 and PBR of 6.13.
weight 0.550% → 0.600% (+0.050 pp)·stock up 10.1% in the 30 days before
Jun 26·entry $254.66·now $248.82Fresh
-2.29%
since Jun 26
AIEQ · Weight increase · 2d
The recent subtle, consecutive weight increases for Johnson & Johnson, moving from 0.58% to 0.59% in AIEQ, are characteristic of a fund that rebalances daily and incorporates immediate market signals. Despite JNJ’s current price of $244.88, placing it at 99% of its 52-week high after a 56.3% one-year return, IBM Watson's NLP likely detected a sustained positive shift in sentiment or fundamental indicators. JNJ's 26.26% ROE and 7.87% revenue growth provide a solid fundamental backdrop that, when combined with fresh news, filings, or social commentary, justifies the fractional upward allocation by this broad market, fundamentals-plus-sentiment hybrid ETF. This precise, daily adjustment aligns with EquBot's strategy of converting real-time data insights into specific portfolio positioning, even for a stock trading at elevated levels.
weight 0.550% → 0.590% (+0.040 pp)·stock up 6.4% in the 30 days before
Jun 25·entry $244.88·now $248.82Fresh
+1.61%
since Jun 25
AIEQ · Weight increase · 2d
stock up 6.3% in the 30 days before
Jun 11·entry $238.33·now $248.82Drifting
+4.40%
since Jun 11
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of Jul 19
While AI ETFs like AIEQ and PQUS have shown mixed but recently trending upward accumulation of JNJ, the value-investing framework concludes a "Fail" due to the current high valuation. This suggests the AI's algorithms may prioritize different factors or growth prospects that override the concern for a significant margin of safety. The AI's actions, by accumulating, appear to contradict a strict value-based approach at current prices.
- Circle of CompetenceThe diversified healthcare conglomerate, with its established market positions across pharmaceuticals and medical devices, demonstrates predictable unit economics suitable for long-term cash flow projections.
- Economic MoatJohnson & Johnson benefits from strong brand recognition, high switching costs for its medical and pharmaceutical products, and substantial scale in research and development, forming a durable economic moat.
- ManagementBased solely on the provided financial snippets, there is insufficient information to assess management's candor, capital allocation discipline, or ownership incentives.
- Financial HealthWhile the reported ROE of 26.26% is strong, a comprehensive assessment of financial health, including long-term ROE trends, operating margin stability, debt profile, and owner earnings, cannot be fully determined from the limited data provided.
- Margin of SafetyWith a P/E ratio approaching 29 and a high EV/EBITDA, the current market price does not offer a defensible margin of safety relative to a conservative estimate of intrinsic value.
Johnson & Johnson largely fits within the circle of competence and possesses a strong economic moat, identifying it as a high-quality business. However, a definitive assessment of management and full financial health is hindered by limited data, and crucially, the current market price offers no discernible margin of safety, resulting in an overall "Fail" for a Buffett-style investment.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.